ISPOR PUBLISHES NEW GLOBAL HEALTH CARE SYSTEMS ROAD MAP- AUSTRALIA MEDICAL DEVICES

Published May 2, 2016
Princeton, NJ—May 2, 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) announced today that it has published a new Global Health Care Systems Road Map—Australia Medical Devices. ISPOR’s Global Health Care Systems Road Maps provide an overview of country-specific, health care delivery systems. The Road Maps focus on reimbursement and pricing approval processes by country in one of three segments—pharmaceutical, medical devices, or diagnostics. The Global Health Care Systems Road Maps can benefit a variety of stakeholders (i.e., health care decision makers, payers, researchers, industry, clinicians, patient representatives, academicians, and students) who are interested in how a given country reimburses and approves pricing for health care technologies. These Road Maps are validated by country-specific health care experts and are periodically updated to reflect changes in the country’s health care delivery system. According to the newly published Global Health Care Systems Road Map—Australia Medical Devices, Australia has a publically funded universal health care system operated by the government’s Department of Health (DoH). Their aim is to provide universal access to all 23.5 million Australian citizens and permanent residents at an affordable or no cost. Medical devices are often referred to as “medical services” in Australia. Australia’s Therapeutic Goods Administration (TGA) is the regulatory body that is involved in many stages of the life cycle of a new medical device before and after it achieves market access in Australia. The ISPOR Global Health Care Systems Road Map—Australia Medical Devices can be found here. Other recently published Global Health Care Systems Road Maps include: Additional information on all of the ISPOR Tools for Health Care Decision Makers can be found here.

###

Related Stories

ISPOR Task Force Addresses Critical Gap in Surrogate Endpoint Guidance

May 28, 2026

Value in Health, announced the publication of an ISPOR Good Practices Report providing guidance on the use of surrogate endpoint evaluation methods in health technology assessment (HTA) decision making. The report, “Methods for Evaluation of Surrogate Endpoints for HTA Decision Making: A Good Practices Report of an ISPOR Task Force,” was published in the May 2026 issue of Value in Health.

How Is Health Valued in the United Kingdom? We Finally Have a Better Answer

May 27, 2026

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a pair of companion articles that together establish both the methodological foundation of the first definitive UK value set for the EQ-5D-5L and the practical implications of adopting it—thus equipping health technology assessment decision makers with a UK value set suitable for informing policy. The articles were featured in the May 2026 issue of Value in Health.

ISPOR Announces 2026-2027 Board of Directors

May 26, 2026

ISPOR—The Professional Society for Health Economics and Outcomes Research announced its 2026-2027 board of directors who will assume office on July 1, 2026.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×